BeiGene, Acerta Btk inhibitors challenging Imbruvica

Data for Bruton's tyrosine kinase inhibitors from BeiGene Ltd. (Beijing, China) and Acerta B.V. (Oss, the Netherlands) reported at the American Society of Hematology (ASH) meeting in Orlando suggest the compounds could pose a challenge to Imbruvica ibrutinib from AbbVie Inc. (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ).

Both BeiGene's BGB-3111 and Acerta's acalabrutinib ( ACP-196) were designed to be more selective against Btk than Imbruvica. ...